8 / 8
Page 31
Notes:
Volume 2
allied
academies
June 11-13, 2018 | London, UK
Neurology and Neuroscience
6
th
International Conference on
L
umbar degenerative disc disease ( DDD ) poses an ongoing
challenge as far as treatment options and alternatives,
especially when considering younger patients. Over 80% of
the adult population presents with one or more episodes of
ongoing-progressive low-back pain ( LBP ). The primary cause
is associated with degeneration of the intervertebral disc and
which is triggered by a decrease of the nucleus pulposus cell
population, asevidenced inhistological studies.Definitely , inthe
presence of a “black disc” without profusion and neurological
compromise, microsurgery or even fusion surgery should not be
contemplated. Numerous percutaneous techniques have been
propagated as proper way to treat this condition throughout
the literature in the past years. They have been primarily
focused on the treatment of the pain generated by the involved
disc and the subsequent segmental insufficiency , without
addressing the degeneration of the disc and for this have had
limited success and remain as pain management tools. Some
significant trials in the past ( i.e. Chondrocyte transplantation
trial ) and the increasing recent research and achievements
with more biological strategies as far as tissue regeneration ,
have motivated the development of a new treatment concept
initially applicable to the lumbar spine which will be presented
and discussed.
Advancements have led to a significant improvement in the
understandingofthecellenvironmentandtissuetransplantation
at a molecular, cellular and immunobiological level. Adipose
tissue has already become a central source of clinical and
research work involving adipose tissue derived progenitor cells.
Endothelial and mesenchymal stem cells derived from adipose
tissue are being considered and used in an array of clinical
conditions and seemtohave clear therapeutic benefits formany
disease conditions including those affecting bone, cartilage and
muscle . The use of an accessible source with abundant cells
which have a high potential for regeneration clearly is superior
in comparison to the chondrocyte option for the lumbar disc.
Mesenchymal cells have a high self renewal capacity and a
potential for multi lineage differentiation. For this , adipose
tissue derived MSCs ( ADMSCs) are optimal candidates for
tissue regeneration and can be obtained from the patient in a
one step procedure-treatment.
Speaker Biography
Walter Bini has completed his Diploma at Westminster School, Simsbury Conn. USA
and Post-graduate degree at Universidad de Zaragoza, Facultad de Medicina,Zaragoza-
Spain. In 2014, he was the Middle East Chairman of ISLASS. He was Head of
Neurosurgery at Sheikh Khalifa General Hospital, UAQ-UAE from 2014-2016. Currently,
he is Consultant Neurosurgeon in Orthopedic department, spine section of Lanzo
Hospital COF, Lanzo d’Intelvi in Italy and also Visiting Consultant Neurosurgeon in
Orthopedic department at Healthpoint Hospital, UAE.
e:
binidr4@gmail.comWalter Bini
Healthpoint Hospital, UAE
Degenerative disc disease ( DDD ): Up-front considerations regarding a truly bio-
functional treatment with mesenchymal adipose tissue derived stem cells